Intramuscular Olanzapine: A Case Series
Author Information
Author(s): Chris J Bushe, Mark Taylor, Mathew Mathew
Primary Institution: Eli Lilly and Company Ltd
Hypothesis
Can intramuscular olanzapine be effective and safe in routine clinical practice for patients with acute psychosis?
Conclusion
Intramuscular olanzapine was generally effective in treating patients with acute psychosis, with no adverse events reported.
Supporting Evidence
- All patients reported improvement in their symptoms after receiving intramuscular olanzapine.
- No adverse events were reported in any of the cases.
- The PANSS-EC scale showed significant reductions in scores for some patients after treatment.
- Patients treated in routine practice had greater severity of psychosis than those in clinical trials.
Takeaway
Doctors gave a medicine called olanzapine to 7 patients who were very upset, and it helped them feel better without causing any problems.
Methodology
A case series of 7 patients treated with intramuscular olanzapine in routine clinical practice, with PANSS-EC scores recorded for some.
Potential Biases
Potential bias in the collection and reporting of data due to the small sample size.
Limitations
The study is based on a small number of cases, and bias in data collection and reporting cannot be excluded.
Participant Demographics
Patients included both males and females with diagnoses of schizophrenia and bipolar disorder, aged from 18 to 65.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website